Clinical Trial Update: Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating tesetaxel as second-line therapy for patients with advanced melanoma and normal serum LDH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• tesetaxel (tesetaxel)

Snippet

Sponsor: Genta Incorporated | Conditions: Melanoma | Phase 2 | Status: UNKNOWN